Therapeutic Sequencing Strategy in Multiple Myeloma Date: 24 th June 2021 (Thursday) Time: 19:00 - 20:40 (GMT+8, HKT) Meeting format: Zoom meeting Address: Salon Room III, Hyatt Regency Hong Kong, 18 Hanoi Road, Tsim Sha Tsui, Kowloon The survival o...
Over the past 25 years, significant progress has been made in the treatment of multiple myeloma (MM) as reflected by the improved overall survival (OS). However, in relapsed and refractory MM (RRMM), median OS decreases with each extra line of thera...
T he Importance of Achieving Deepest Possible Response and Continuous Therapy While improving long-term survival for patients with MM is desirable, clinical data suggested that complete response (CR) to treatment is associated with survival outcomes...
Management of Relapsed and Refractory Multiple Myeloma Date: 25 February 2021 (Thursday) Time: 19:15 - 20:40 (GMT+8, HKT) Meeting format: Zoom meeting Webinar on Management of Relapsed and Refractory Multiple Myeloma Multiple myeloma (MM) is charact...
Since June 2020, a webinar series known as Guerbet APAC TV so far has reached 81 countries/regions worldwide since it has been broadcasted. This year their 6 live webinars cover various topics in diagnostic imaging such as the application of artif...
Digital Polymerase Chain Reaction and Its Diagnostic Applications Quantitative real time polymerase chain reaction (RT-PCR) is widely used in clinical detection. However, the limitations of the technology including easy affected by sample inhibitors...
Acute myeloid leukaemia (AML) accounts for approximately 80% of acute leukaemia diagnosed in adults and the 5-year overall AML survival rate is 15%. Mutational status of FMS-like tyrosine kinase 3 (FLT3) is now well recognised as delineating a subty...
